BeiGene, Ltd. (ONC) — Quality & forensics
As of 2026-09-22 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 31
- Quality 64
- Growth 86
- Balance sheet 80
- Cash quality 82
- Capital allocation 11
- Momentum 80
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the ONC chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-22
Quick answers
What is BeiGene, Ltd.'s Closelook quality reading?
The composite reads 64/100 across 7 modules, as of 2026-09-22: valuation 31, quality 64, growth 86, balance sheet 80, cash quality 82, capital allocation 11, momentum 80. Closelook scores are research diary readings, not ratings or investment advice.
What is BeiGene, Ltd.'s Altman Z-Score?
6.33, which sits in the safe zone (above 2.99) as of 2026-09-22. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is BeiGene, Ltd.'s Piotroski F-Score?
7 of 9, as of 2026-09-22. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does BeiGene, Ltd.'s Beneish M-Score indicate?
-2.64 — below the −1.78 manipulation-risk threshold, as of 2026-09-22. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- CAI Caris Life Sciences, Inc. Common Stockindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- DNA Ginkgo Bioworks Holdingsindustry
- RXRX Recursion Pharmaceuticals Incindustry
- IBRX Immunitybio Incindustry
- HALO Halozyme Therapeutics Incindustry
- SMMT Summit Therapeutics PLCindustry
- SRPT Sarepta Therapeutics Incindustry
- GMAB Genmab ASindustry
- CRSP Crispr Therapeutics AGindustry
- TGTX TG Therapeutics Incindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- EXEL Exelixis Incindustry